KEY TAKEAWAYS: Ribociclib, a CDK4/6 inhibitor, is a promising drug in the treatment of early-stage and metastatic breast cancer, particularly when used in combination with endocrine therapy. The NATALEE study underscores the efficacy of Ribociclib, demonstrating a significant reduction in disease recurrence. Despite potential side effects, Ribociclib contributes to improved survival rates and quality of … Continue reading Revolutionizing Breast Cancer: Ribociclib Unveiled